Avita Medical Release: Granted Japanese Patent Expands Commercial Rights for ReCell® Spray-On Skin® Technology in Asia

Published: Apr 10, 2013

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - April 10, 2013) -

Highlighted Links

Japanese Patent Covers Technology Embodied in ReCell® Spray-On Skin®
Grant of Broad Claims Related to 'Composition of Matter', 'Methods' and 'Device'
Granted Claims Confer Exclusive, Long-Term Commercial Rights

Regenerative medicine Company Avita Medical Ltd. (ASX: AVH) (PINKSHEETS: AVMXF) (OTCQX: AVMXY) is pleased to announce that it has secured the grant of Japanese Patent No. 5214085 "Cell Suspension Preparation Technique and Device" by the Japanese Patent Office.

Japan is the world's third largest healthcare market behind the US and Europe with the longest life expectancy and an ageing population.

The granted patent protects the Company's broad claims related to the preparation and composition of a cell suspension comprised of the patient's own epithelial cells (an autologous suspension), and the general therapeutic use of the regenerative epithelial cell suspension.

The patented technology is incorporated into the Company's lead regenerative product, ReCell® Spray-On Skin®, used in the treatment of chronic and acute wounds and a wide range of reconstructive and aesthetic procedures. Mr Andrew Quick, Avita Medical Vice President of Research and Technology, commented on the news: "The Company is continuing to build its intellectual property portfolio with a widening range of potential products and applications. The Japanese patent, adding to the Company's granted patents in Europe, the US and Australia, are major assets that confer certainty, provide a protected platform on which to broaden the range of product offerings by the Company, and significantly increase the commercial value of the platform technology."

These patents deliver significant commercial advantages and offer long term protection in these territories for the Company's products based on its proprietary technology platform.

"The market potential for this platform technology is immense," said Avita Medical CEO, Dr William Dolphin. "This patent grant further validates Avita's unique capabilities in harnessing the body's regenerative capabilities with application to a wide range of clinical indications. The patent secures additional protection for our intellectual property in the rapidly growing field of regenerative medicine."

"Maintaining commercial exclusivity for our regenerative products through a robust international patent portfolio is fundamental to our corporate strategy," Dr Dolphin added.

ABOUT AVITA MEDICAL LTD.

Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell® Spray-On Skin®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.